⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4795496 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL8007870 | 0.98 | — | — | |
| Hydrochloric Acid SCHEMBL8007874 | 0.98 | — | — | |
| SCHEMBL5050144 | 0.84 | — | — | |
| SCHEMBL16690908 | 0.84 | — | — | |
| SCHEMBL4799368 | 0.76 | TTR (0.38) | — | |
| SCHEMBL4800614 | 0.72 | NQO2 (0.38) | — | |
| SCHEMBL5888763 | 0.71 | — | — | |
| SCHEMBL4801113 | 0.70 | ALDH1A1 (0.31) | — | |
| SCHEMBL4801124 | 0.70 | ALDH1A1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605459-B2 | Protein-drug conjugates comprising camptothecin analogs and methods of use thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-12497460-B2 | Anti-MSR1 antibodies and methods of use thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2025-12-16 | — | — | US | disclosed |
| US-12419963-B2 | Diels-Alder conjugation methods | REGENERON PHARMACEUTICALS, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250171622-A1 | BIS-OCTAHYDROPHENANTHRENE CARBOXAMIDE DERIVATIVES AND PROTEIN CONJUGATES THEREOF FOR USE AS LXR AGONISTS | REGENERON PHARMACEUTICALS, INC. | 2025-05-29 | — | — | US | disclosed |
| US-20250064954-A1 | STEROIDS AND ANTIBODY-CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. | 2025-02-27 | — | — | US | disclosed |
| US-12209180-B2 | Bis-octahydrophenanthrene carboxamide derivatives and protein conjugates thereof for use as LXR agonists | REGENERON PHARMACEUTICALS, INC. (US) | 2025-01-28 | — | — | US | disclosed |
| US-20240408223-A1 | HYDROPHILIC LINKERS FOR ANTIBODY DRUG CONJUGATES | REGENERON PHARMA (US) | 2024-12-12 | — | — | US | disclosed |
| US-12144864-B2 | Tubulysins and protein-tubulysin conjugates | REGENERON PHARMACEUTICALS, INC. (US) | 2024-11-19 | — | — | US | disclosed |
| US-12134631-B2 | Hydrophilic linkers for antibody drug conjugates | REGENERON PHARMACEUTICALS, INC. (US) | 2024-11-05 | — | — | US | disclosed |
| US-20240342299-A1 | STEROIDS AND ANTIBODY-CONJUGATES THEREOF | REGENERON PHARMA (US) | 2024-10-17 | — | — | US | disclosed |
| US-11377502-B2 | Anti-MSR1 antibodies and methods of use thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| US-20220080052-A1 | BIS-OCTAHYDROPHENANTHRENE CARBOXAMIDE DERIVATIVES AND PROTEIN CONJUGATES THEREOF FOR USE AS LXR AGONISTS | REGENERON PHARMACEUTICALS, INC. | 2022-03-17 | — | — | US | disclosed |
| US-20220072141-A1 | PROTEIN-DRUG CONJUGATES COMPRISING CAMPTOTHECIN ANALOGS AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2022-03-10 | — | — | US | disclosed |
| US-20210332080-A1 | HYDROPHILIC LINKERS FOR ANTIBODY DRUG CONJUGATES | REGENERON PHARMACEUTICALS, INC. | 2021-10-28 | — | — | US | disclosed |
| US-20210040144-A1 | STEROIDS AND PROTEIN-CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. | 2021-02-11 | — | — | US | disclosed |
| US-10711032-B2 | Steroids and protein-conjugates thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-20190070306-A1 | OPTIMIZED TRANSGLUTAMINASE SITE-SPECIFIC ANTIBODY CONJUGATION | REGENERON PHARMACEUTICALS, INC. | 2019-03-07 | — | — | US | disclosed |
| US-20180155389-A1 | STEROIDS AND PROTEIN-CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. | 2018-06-07 | — | — | US | disclosed |
| US-7417040-B2 | Fused tricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-08-26 | — | — | US | disclosed |
| US-20050250753-A1 | Fused tricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogenase 3 | BRISTOL-MYERS SQUIBB COMPANY | 2005-11-10 | — | — | US | disclosed |